Humalog

The fight for affordable insulin

The price of Humalog, more commonly used by type 1 patients, also saw its price rise 585% from $35 to $234 between 2001 and 2015. ... Lilly’s authorised generic. One company, Eli Lilly, has responded to the pleas for more affordable insulins, and

Sanofi joins Lilly in insulin price cut, but lawmakers have lost patience

Lilly’s recent move to launch a cut-price version of its Humalog brand, which has come under particularly strong criticism after its price rose from $35 to $234 per vial

FDA approves Sanofi's follow-on version of Lilly’s Humalog

Eli Lilly is facing the threat of competition to its big-selling short-acting insulin Humalog after Sanofi claimed full FDA approval for a rival version. ... Now Sanofi can go after one of Lilly’s big brands - Humalog made $2.1bn in sales for Lilly in

Lilly mulls divestment of its animal health operations

Off-loading Elanco could raise billions of dollars to invest in the pharma business at a time when it is facing biosimilar competition from Sanofi for its best-selling drug Humalog

Payback time nears as Sanofi gets CHMP backing for biosimilar Humalog

Panel recommends insulin Lispro Sanofi to treat diabetes. Sanofi's biosimilar version of Eli Lilly's mealtime insulin product Humalog has been recommended for approval in the EU, raising the prospect ... The importance of Humalog to Lilly cannot be

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 [ Next 5 results ]